Striatal dopamine D2, adenosine A2A and cannabinoid CB1 receptors balance as a target against non-cognitive symptoms in a mouse model of Alzheimer's disease
Pharmacology Biochemistry and Behavior · 2025-04 · 249 · 173970
DOI: 10.1016/j.pbb.2025.173970 ↗Kurz gefasst
Fachartikel in der Zeitschrift Pharmacology Biochemistry and Behavior, 2025-04. Verfasst von Laura Gómez-Acero und 4 weiteren Autor:innen. Beteiligte Einrichtung: Pharmacology Unit, Department of Pathology and Experimental Therapeutics, School of Medicine and Health Sciences, Institute of Neurosciences, Univers…. Hauptthemen laut MEDLINE: Alzheimer Disease, Receptor, Cannabinoid, CB1, Receptor, Adenosine A2A, Receptors, Dopamine D2. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 47 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: National Plan for Scientific and Technical Research and Innovation, European Social Fund Plus, Departament de Recerca i Universitats, Generalitat de Catalunya.
Themen: Demenz
Abstract (Originalsprache)
Behavioral and psychological symptoms of dementia are almost ubiquitous in Alzheimer's disease (AD) but current therapies are not fully effective and safe. In this study, we aim to evaluate the role played by the interplay among striatal D2, adenosine A2A (A2AR) and cannabinoid CB1 (CB1R) receptors in some of these non-cognitive impairments in a well-established animal model of AD, the double transgenic APP/PS1 mice. Our results reveal that the alterations existing in the ratios between these three receptors significantly correlate with the sensorimotor gating and the social interaction impairments occurring in APP/PS1 mice at 12 months of age. Moreover, the pharmacological stimulation of A2AR and CB1R blunted the sensorimotor gating deficiencies in APP/PS1 mice. To note, we observed some age-dependent differences among male and female mice. In conclusion, the present study provides evidence for the contribution of an altered interplay between dopaminergic, adenosinergic and endocannabinoid systems in the sensorimotor gating deficits and social withdrawal occurring in AD and points to A2AR and CB1R as a potential target to reverse these non-cognitive symptoms in AD patients.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Pharmacology Unit, Department of Pathology and Experimental Therapeutics, School of Medicine and Health Sciences, Institute of Neurosciences, University of Barcelona, L'Hospitalet de Llobregat, Spain; Neuropharmacology…
Förderung
- National Plan for Scientific and Technical Research and Innovation
- European Social Fund Plus
- Departament de Recerca i Universitats, Generalitat de Catalunya
- European Regional Development Fund
- Ministerio de Ciencia e Innovación
- Agencia Estatal de Investigación
- Federación Española de Enfermedades Raras
- Ministerio de Ciencia, Innovación y Universidades
Zitieren
APA
Gómez-Acero, L., Sánchez-Fernández, N., Subirana, P., Ciruela, F., & Aso, E. (2025). Striatal dopamine D2, adenosine A2A and cannabinoid CB1 receptors balance as a target against non-cognitive symptoms in a mouse model of Alzheimer's disease. Pharmacology Biochemistry and Behavior, 249, 173970. https://doi.org/10.1016/j.pbb.2025.173970
Vancouver
Gómez-Acero L, Sánchez-Fernández N, Subirana P, Ciruela F, Aso E. Striatal dopamine D2, adenosine A2A and cannabinoid CB1 receptors balance as a target against non-cognitive symptoms in a mouse model of Alzheimer's disease. Pharmacology Biochemistry and Behavior. 2025;249:173970. doi:10.1016/j.pbb.2025.173970
BibTeX
@article{GmezAcero2025,
author = {Gómez-Acero, Laura and Sánchez-Fernández, Nuria and Subirana, Paula and Ciruela, Francisco and Aso, Ester},
title = {Striatal dopamine D2, adenosine A2A and cannabinoid CB1 receptors balance as a target against non-cognitive symptoms in a mouse model of Alzheimer's disease},
journal = {Pharmacology Biochemistry and Behavior},
year = {2025},
volume = {249},
pages = {173970},
doi = {10.1016/j.pbb.2025.173970}
}
EUVIMED